He was treated with dasatinib and followed-up; 6 months later, he achieved a complete molecular response. 
dasatinib
Development of AML without karyotype abnormalities including the Ph chromosome in a CML patient on second-generation TKI therapy.A 58-year-old man was diagnosed with accelerated phase chronic myelogenous leukemia (CML).  Treatment with a tyrosine kinase inhibitor (TKI) achieved a successful outcome.  However, approximately 10% of CML cases develop clonal cytogenetic changes in Ph-negative cells during TKI treatment, and rarely, cases of Ph-negative myelodysplastic syndrome or AML are reported.  We suggest vigilant monitoring during TKI therapy and stress the importance of further analysis based on similar accumulated cases.
TKI